Effector, Pfizer and Merck to initiate Phase II combination trial for colorectal cancer

Effector Therapeutics has signed a clinical collaboration and supply agreement with Pfizer and Merck to initiate a Phase II clinical trial of immuno-oncology drugs combination to treat microsatellite stable colorectal cancer (CRC) patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news